Ketogenic Diet & Parkinson’s Disease – Detailed Study Notes

Background: Parkinson’s Disease (PD)

• Chronic, progressive neuro-degenerative disorder characterized by loss of dopaminergic neurons ➜ dopamine deficiency.
• Motor symptoms
  • Limb stiffness, impaired balance, tremor, bradykinesia (slowness of movement/reflexes).
• Non-motor symptoms
  • Cognitive decline, behavioral disturbances, sleep problems, constipation, anxiety.
• Epidemiology
  • Affects nearly $1\,000\,000$ Americans; prevalence projected to double by $2040$.
  • Celebrity example: Michael J. Fox diagnosed at $29$ → underscores early-onset possibility.

Ketogenic Diet (KD) Rationale

• Macros: $70\text{-}75\%$ fat, $20\%$ protein, $5\text{-}10\%$ carbohydrates.
• Mechanistic hypotheses
  • Produces ketone bodies (alternative neuronal fuel).
  • ↓ systemic & neuro-inflammation.
  • Improves mitochondrial/neuronal metabolism.
  • Potentially modulates dopamine synthesis & signaling.
• Clinical promise: may slow progression or reduce severity of selected motor & non-motor PD symptoms.

Key Outcome Instrument

• Unified Parkinson’s Disease Rating Scale (UPDRS)
  1. Non-motor experiences of daily living.
  2. Motor experiences of daily living.
  3. Motor examination.
  4. Motor complications.
• Higher scores = worse symptoms.

Study 1: Ketogenic Diet ➜ Motor & Non-Motor Symptoms

• Participants: $N=16$ ( $11$ ♂, $5$ ♀ ).
• Duration: $12$ weeks; Zoom follow-ups weekly.
• Diet prescription (based on BMI):
  • Baseline menu: $1750$ kcal → $152$ g fat (≈$78\%$ kcal), $75$ g protein (≈$17\%$), $16$ g net carbs (≈$3\text{-}4\%$).
  • Higher-need participants received $+500$ kcal snacks.
• Monitoring tools
  • Keto Mojo blood ketone meter (daily); fasting glucose (weekly).
  • Food logged via MyFitnessPal or paper.
• Additional scale: Parkinson’s Anxiety Scale ( $12$ items, $3$ sub-scales: persistent, episodic, avoidance ).
• Results
  • UPDRS Part 1 ↓ by $1.06$ points (all participants) & $0.93$ (subset maintaining ketosis, $n=14$) ⇒ significant.
  • No sig. change in Parts 2-4.
  • Anxiety Scale ↓ by $3.06$ points ⇒ significant.
• Interpretation: KD improved non-motor domains & anxiety; motor domains unchanged.

Study 2: MCT Oil + KD Feasibility (Choi et al.)

• Purpose: Assess whether medium-chain triglyceride (MCT) oil accelerates/maintains ketosis with less dietary change.
• Participants: $N=16$ ( $9$ ♂, $7$ ♀ ).
• Outcome tools: UPDRS + Non-Motor Symptom Scale (NMSS, $30$ items).
• Phase 1 (inpatient, double-blind, $1$ week)
  • KD group: $7$ pts; macros $80\%$ fat, $10\text{-}15\%$ protein, $5\text{-}10\%$ carbs.
  • Standard diet group: $9$ pts; macros $35\%$ fat, $10\text{-}15\%$ protein, $50\text{-}55\%$ carbs.
• Phase 2 (outpatient, $2$ weeks)
  • Both groups received KD cookbook + MCT supplementation.
  • Meals: $500$ kcal + $2$ Tbsp MCT; snacks: $250$ kcal + $4$ tsp MCT.
• Ketosis tracking: red symbols (KD) maintained higher β-hydroxybutyrate throughout; blue (standard) lower.
• Results
  • NMSS: Standard diet ↓ from $43.8$ → $33.0$ (significant urinary & pain relief).
  • KD ↓ $43.8$ → $31.5$ (similar magnitude).
  • UPDRS: No significant change in either group.
• Conclusion: MCT-assisted KD feasible; no motor benefit detected within $3$ weeks; potential non-motor relief irrespective of baseline diet.

Study 3: Low-Fat vs Ketogenic Diet (Phillips et al.)

• Participants: $N=47$ ( $31$ ♂, $16$ ♀ ).
• Duration: $8$ weeks.
• Daily diet templates (based on $1750$ kcal + optional $500$ kcal snack).
  • KD group $n=24$: $125$ g fat, $75$ g protein, $16$ g net carbs.
  • Low-fat group $n=23$: $42$ g fat, $75$ g protein, $246$ g net carbs.
• Monitoring: Daily glucose & ketone readings; updated UPDRS.
• Ketosis profile: KD maintained 1.15\,\text{mmol·L}^{-1}; low-fat stayed at 0.16\,\text{mmol·L}^{-1}.
• Results (mean score change)
  • Parts 1-3: ↓ in both groups (no between-group difference).
  • Part 4: Low-fat $\Delta=0$; KD $\Delta=-1.56$ (significant improvement in motor complications).
• Conclusion: Both diets safe/effective; KD may confer extra benefit for non-motor & complication domains.

Synthesis & Practical Take-aways

• Consistent findings
  • KDs achieve and sustain nutritional ketosis in PD cohorts.
  • Non-motor symptoms (anxiety, urinary issues, pain) show modest but significant improvements.
  • Motor domain effects mixed; only one study (Phillips) found ↓ motor complications.
• Magnitude of change modest (≈$1$-$3$ points) → clinical relevance varies by baseline severity.
• Patient-centered considerations
  • Dietary restrictiveness & potential adverse effects (GI distress, nutrient deficiencies, social limitations) may offset benefits.
  • Decision should weigh symptom relief vs dietary burden.

Limitations Across Studies

• Lack of true control • no weight-stable comparison groups ➜ cannot separate diet composition vs weight loss effects.
• Small sample sizes ( $16$-$47$ ) & short durations ( $3$-$12$ weeks ).
• Heterogeneous disease duration (e.g., Choi: standard $10$ yrs vs KD $15$ yrs) confounds motor outcomes.
• UPDRS inter-study scoring versions differ.
• Adherence self-reported (food logs) ► risk of reporting bias.

Future Research Directions

• Include weight-maintained control groups to isolate macronutrient effects.
• Long-term (>$12$ months) adherence & sustainability trials.
• Stratify by disease stage/duration to evaluate progression-specific efficacy.
• Explore mechanistic biomarkers (dopamine metabolites, inflammatory cytokines, mitochondrial function).
• Investigate combination therapies (KD + pharmacologic agents) & patient-reported quality-of-life metrics.

Ethical & Practical Implications

• Autonomy: Patients must be fully informed of dietary demands & side-effect profile.
• Equity: Access to KD foods, monitors, dietitians may vary socio-economically.
• Clinical integration: Coordination with neurologists & dietitians essential to adjust dopaminergic meds when metabolism shifts.